30 Years of Pharmaceutical Technology and What Lies Ahead - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

30 Years of Pharmaceutical Technology and What Lies Ahead
A review of advancements in areas such as active ingredients, formulation, technology, regulation, and analytical testing.

Pharmaceutical Technology


In the area of reduced sample sizes, instruments have become more sensitive over the years, and detector technology has improved. As a result, users have been able to generate the same information with smaller sample sizes. Techniques for sample preparation have improved as well, enabling purer samples to be attained. In addition, sample preparation has become largely automated. These developments together brought greater repeatability and more-precise results.

References

1. S.King, "The Evolving Pharmaceutical Value Chain: Forecasting Growth for Small and Large Molecules," Pharm. Technol. 30 Technology Outlook: APIs, Intermediates, and Formulation suppl. s6–s10 (2006).

2. D.A. Kessler, Presentation at the Food and Drug Law Institute Annual Meeting, Washington, DC, Dec. 10, 1996, http://www.fda.gov/speeches/kessler.html (accessed May 29, 2007).

3. P.Van Arnum, "The Changing Fortunes of APIs," Pharm. Technol. 31 (1), 52–58 (2007).

4. M.J. Akers, S.L. Nail, and M.J. Groves, "Top 10 Current Technical Issues in Parenteral Science Revisited, 1997," Pharm. Technol. 21 (7), 126–134 (1997).

5. "Thimerosal in Vaccines," http://www.fda.gov/ (accessed June 6, 2007).

6. M. Rios, "Bringing Formulations to Size: Strategies for Micro- and Nanoparticle Development," Pharm. Technol. 28 (11), 40–53 (2004).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
30%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
8%
All of the above.
45%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here